

FluMist provides higher efficacy in clinical trial setting with 54.4% reduction in Influenza cases compared with IIV and in addition to comparable vaccine effectiveness to IIV, FluMist may have the potential to offer durable protection

across the influenza season. FluMist demonstrated durable efficacy, up to 12 months of protection against influenza vs placebo, and may protect children for the entire flu season

- FluMist offers more stable protection across the flu season than IIV
- Intranasal route of administration of FluMist may result in increased vaccine uptake compared to IIVs due to preferred route of administration
- FluMist induces a broad and distinct 3-way immune response beginning at the site of infection— the nose
- FluMist offers indirect benefits and may help reduce infections in children and adults.
- Retrospective studies demonstrated higher acceptance and preference by parents and adults for FluMist
 - In Switzerland, 97% of adults preferred the intranasal option when offered a choice between an inactivated intranasal influenza vaccine and an IIV.
 - In France, 81% of parents have a greater acceptance of FluMist than injection for their children
 - The vaccination rate for children aged 2-6 years in Finland doubled after FluMist was made available.
 - The introduction of FluMist in Wales helped increase vaccination uptake from 41% to 71.5% among 3-year-old children, a group with a traditionally lower rate than school-aged children.